On this page

Acetic Acid

Prescription NDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Acetic Acid
Generic name
Acetic Acid
Dosage form
Irrigant
Route
Irrigation
Marketing category
NDA · NDA
Labeler
Baxter Healthcare Corporation
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
2
Packages
3
Data completeness
77% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Acetic Acid .25 g/100mL 197305 View
Acetic Acid 250 mg/100mL 197305 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Irrigant
Route of administration
Irrigation
Presentations
5

Regulatory status

Source: Drugs@FDANDC Directory
Application number
018523
Application type
NDA · New Drug Application
Approval date
February 19, 1982
Sponsor
BAXTER HLTHCARE
Products on application
1
Submissions recorded
14
Products approved under application 018523.
Product Trade name Form Strength Ingredient Status TE Flags
018523-001 ACETIC ACID 0.25% IN PLASTIC CONTAINER SOLUTION ACETIC ACID, GLACIAL Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 018523.
Type No. Action Status Date Review
Supplement 22 Manufacturing (CMC) Approved September 26, 2014 Standard
Supplement 20 Manufacturing (CMC) Approved September 28, 2011 —
Supplement 15 Labeling Approved May 26, 1999 —
Supplement 12 Manufacturing (CMC) Approved September 30, 1994 Standard
Supplement 13 Manufacturing (CMC) Approved September 14, 1993 Standard
Supplement 10 Manufacturing (CMC) Approved November 14, 1991 Standard
Supplement 11 Manufacturing (CMC) Approved March 26, 1991 Standard
Supplement 9 Manufacturing (CMC) Approved May 18, 1990 Standard
Supplement 8 Manufacturing (CMC) Approved July 26, 1989 Standard
Supplement 7 Manufacturing (CMC) Approved October 30, 1986 Standard
Supplement 6 Labeling Approved June 26, 1985 —
Supplement 2 Manufacturing (CMC) Approved January 24, 1985 Standard
Supplement 4 Manufacturing (CMC) Approved February 28, 1984 Standard
Original application 1 Type 5 - New Formulation or New Manufacturer Approved February 19, 1982 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20230823). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20230823 HUMAN PRESCRIPTION DRUG · 20180202

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE 0.25% Acetic Acid Irrigation, USP, is indicated as a constant or intermittent bladder rinse to help prevent the growth and proliferation of susceptible urinary pathogens (especially ammonia forming bacteria) in the management of patients who require prolonged placement of an indwelling urethral catheter. It also may be used for periodic irrigation of an indwelling catheter to help maintain patency by reducing the formation of calcium encrustations.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION As required for urologic irrigation. 0.25% Acetic Acid Irrigation USP may be administered by gravity drip via an administration set connected to an indwelling urethral catheter designed for continuous or intermittent two-way flow. For continuous or intermittent irrigation, the rate of administration will correspond roughly to the rate of urine flow and should be adjusted to maintain a urinary effluent pH of 4.5 to 5.0. Nitrazine or other pH paper may be used to monitor pH, preferably at least four times daily. Drip rate should be adjusted as necessary to maintain desired pH; increasing flow rate reduces pH value and vice versa. With continuous or intermittent irrigation, each patient will require a volume of approximately 500 to 1500 mL per 24 hours. Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store. This drug product should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS 0.25% Acetic Acid Irrigation USP is not for injection. This solution is contraindicated for irrigation during transurethral surgical procedures.

WARNINGS FOR UROLOGIC IRRIGATION ONLY. NOT FOR INJECTION. Use of this solution in patients with mucosal lesions of the urinary bladder may be harmful due to irritation of the lesion. Absorption via open lesions of the bladder mucosa may result in systemic acidosis. Do not warm above 150°F (66°C). After opening container, the contents should be used promptly in order to minimize the possibility of bacterial growth or pyrogen formation. Discard unused portion of irrigating solution since it contains no preservative.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Systemic acidosis, pain, and hematuria have been reported in patients receiving urinary bladder irrigation with 0.25% acetic acid solution. If an adverse reaction does occur, discontinue administration of the irrigant, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination, if deemed necessary.

Description

openFDA Drug Labeling

DESCRIPTION Each 100 mL contains: Glacial Acetic Acid USP 0.25 g Water for Injection USP qs pH: 3.1 (2.8-3.4) Calculated Osmolarity: 42 mOsmol/liter The formula of the active ingredient is: Ingredient Molecular Formula Molecular Weight Glacial Acetic Acid USP CH 3 COOH 60.05 0.25% Acetic Acid Irrigation USP is a prediluted, sterile, nonpyrogenic aqueous solution suitable for urologic irrigation. It contains no preservatives or added buffers. The solution is hypotonic. The plastic container is a copolymer of ethylene and propylene formulated and developed for parenteral drugs. The copolymer contains no plasticizers and exhibits virtually no leachability. The plastic container is also virtually impermeable to vapor transmission and therefore, requires no overwrap to maintain the proper drug concentration. The safety of the plastic container has been confirmed by biological evaluation procedures. The material passes Class Vl testing as specified in the U.S. Pharmacopeia for Biological Tests — Plastic Containers. These tests have shown that the container is nontoxic and biologically inert. Not made with natural rubber latex, PVC or DEHP.

OVERDOSAGE Systemic absorption is unlikely unless there are open lesions of the bladder mucosa that have gone undetected. In such event, discontinue the irrigation, evaluate the patient for possible systemic acidosis, intravascular hemolysis, and circulatory overload and institute appropriate countermeasures as indicated. See WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS .

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED 0.25% Acetic Acid Irrigation USP is supplied sterile and nonpyrogenic in 1000 mL and 500 mL PICTM (Plastic Irrigation Containers) packaged 16 per case. NDC Cat. No. Size 0.25% Acetic Acid Irrigation USP 0264-2304-00 R6600-01 1000 mL 0264-2304-10 R6601-01 500 mL Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). [See USP Controlled Room Temperature.] However, brief exposure up to 40°C does not adversely affect the product. Do not warm above 150°F (66°C).

Adverse event reports

Source: openFDA FAERS
384
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: ACETIC ACID. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Recalls

Source: FDA Enforcement
Drug recall enforcement reports associated with this product.
Classification Reported Firm Reason Status
Class II December 27, 2017 B. Braun Medical Inc Presence of Particulate Matter: identified as polyethylene, which is consistent with the material used to manufacture the contain cap Terminated

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0264-2304-00 0264-2304 B. Braun Medical Inc. 16 CONTAINER in 1 CASE (0264-2304-00) / 1000 mL in 1 CONTAINER August 6, 1979
0264-2304-10 0264-2304 B. Braun Medical Inc. 16 CONTAINER in 1 CASE (0264-2304-10) / 500 mL in 1 CONTAINER August 6, 1979
0338-0656-04 0338-0656 Baxter Healthcare Corporation 1000 mL in 1 BOTTLE, PLASTIC (0338-0656-04) February 19, 1982
0264-2304 0264-2304 B. Braun Medical Inc. — August 6, 1979
0338-0656 0338-0656 Baxter Healthcare Corporation — February 19, 1982

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts
Enforcement FDA Recall records

Generated September 25, 2026 · 12 sections on this page.